{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:29:37Z","timestamp":1788431377646,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,17]]},"DOI":"10.7759\/cureus.90268","type":"journal-article","created":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T07:52:52Z","timestamp":1755417172000},"source":"Crossref","is-referenced-by-count":2,"title":["Translating Trial to Treatment: A Scoping Review of Resmetirom First Year in Real-World Use for Moderate to Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis"],"prefix":"10.7759","author":[{"given":"Kanika","family":"Vats","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mazhar","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023, 79:1542-56. 10.1016\/j.jhep.2023.06.003","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf094","article-title":"NAFLD vs MASLD (metabolic dysfunction-associated steatotic liver disease) - why the need for a change of nomenclature?","volume":"110","author":"Gastaldelli A","year":"2025","unstructured":"Gastaldelli A, Newsome PN. NAFLD vs MASLD (metabolic dysfunction-associated steatotic liver disease) - why the need for a change of nomenclature?. J Clin Endocrinol Metab. 2025, 110:e2407-10. 10.1210\/clinem\/dgaf094","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-20538-0_2","article-title":"Global epidemiology and risk factors for nonalcoholic fatty liver disease","author":"Chowdhury A","unstructured":"Chowdhury A, Younossi ZM. Global epidemiology and risk factors for nonalcoholic fatty liver disease. Alcoholic and Non-alcoholic Fatty Liver Disease. 2016 (ed): Springer, Cham, Switzerland; 10.1007\/978-3-319-20538-0_2"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref6","article-title":"Nonalcoholic Fatty Liver","author":"Kudaravalli P","year":"2025","unstructured":"Kudaravalli P, John S. Nonalcoholic Fatty Liver. StatPearls. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116069","article-title":"Roles of immune dysregulation in MASLD","volume":"170","author":"Dong T","year":"2024","unstructured":"Dong T, Li J, Liu Y, et al.. Roles of immune dysregulation in MASLD. Biomed Pharmacother. 2024, 170:116069. 10.1016\/j.biopha.2023.116069","journal-title":"Biomed Pharmacother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-015-0260-z","article-title":"Pathogenesis of hepatocellular carcinoma development in non alcoholic fatty liver disease","volume":"14","author":"Shetty K","year":"2015","unstructured":"Shetty K, Chen J, Shin JH, Jogunoori W, Mishra L. Pathogenesis of hepatocellular carcinoma development in non alcoholic fatty liver disease. Curr Hepatol Rep. 2015, 14:119-27. 10.1007\/s11901-015-0260-z","journal-title":"Curr Hepatol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2019.07.013","article-title":"Are lifestyle therapies effective for NAFLD treatment?","volume":"30","author":"El-Agroudy NN","year":"2019","unstructured":"El-Agroudy NN, Kurzbach A, Rodionov RN, O'Sullivan J, Roden M, Birkenfeld AL, Pesta DH. Are lifestyle therapies effective for NAFLD treatment?. Trends Endocrinol Metab. 2019, 30:701-9. 10.1016\/j.tem.2019.07.013","journal-title":"Trends Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002770","article-title":"FDA approves Resmetirom: groundbreaking treatment for NASH liver scarring in moderate to advanced fibrosis","volume":"87","author":"Waheed A","year":"2025","unstructured":"Waheed A, Gul MH, Shabbir MU, Raja HA, Wardak AB, Hussaini H, Shah Y. FDA approves Resmetirom: groundbreaking treatment for NASH liver scarring in moderate to advanced fibrosis. Ann Med Surg (Lond). 2025, 87:1088-91. 10.1097\/MS9.0000000000002770","journal-title":"Ann Med Surg (Lond)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison SA","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al.. A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis. N Engl J Med. 2024, 390:497-509. 10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-00206-JC","article-title":"In NASH with liver fibrosis, resmetirom improved NASH resolution and reduced fibrosis at 1 y","volume":"177","author":"Mironova M","year":"2024","unstructured":"Mironova M, Sherker AH. In NASH with liver fibrosis, resmetirom improved NASH resolution and reduced fibrosis at 1 y. Ann Intern Med. 2024, 177:JC63. 10.7326\/ANNALS-24-00206-JC","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1657","article-title":"Effects of Resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison SA","year":"2021","unstructured":"Harrison SA, Bashir M, Moussa SE, McCarty K, Pablo Frias J, Taub R, Alkhouri N. Effects of Resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol Commun. 2021, 5:573-88. 10.1002\/hep4.1657","journal-title":"Hepatol Commun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00202-9","article-title":"EASL Congress 2023","volume":"8","author":"Thomas H","year":"2023","unstructured":"Thomas H. EASL Congress 2023. Lancet Gastroenterol Hepatol. 2023, 8:P700. 10.1016\/s2468-1253(23)00202-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/livers4010010","article-title":"Resmetirom: finally, the light at the end of the NASH tunnel?","volume":"4","author":"Lonardo A","year":"2024","unstructured":"Lonardo A. Resmetirom: finally, the light at the end of the NASH tunnel?. Livers. 2024, 4:138-41. 10.3390\/livers4010010","journal-title":"Livers"},{"key":"ref16","article-title":"Resmetirom","year":"2024","unstructured":"Resmetirom. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2024."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70025","article-title":"Unveiling Resmetirom: a systematic review and meta-analysis on its impact on liver function and safety in non-alcoholic steatohepatitis treatment","volume":"8","author":"Hashim HT","year":"2024","unstructured":"Hashim HT, Alhatemi AQ, Riaz S, et al.. Unveiling Resmetirom: a systematic review and meta-analysis on its impact on liver function and safety in non-alcoholic steatohepatitis treatment. JGH Open. 2024, 8:e70025. 10.1002\/jgh3.70025","journal-title":"JGH Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: practical clinical applications for initiating and monitoring Resmetirom in patients With MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin M","year":"2024","unstructured":"Noureddin M, Charlton MR, Harrison SA, et al.. Expert panel recommendations: practical clinical applications for initiating and monitoring Resmetirom in patients With MASH\/NASH and moderate to noncirrhotic advanced fibrosis. Clin Gastroenterol Hepatol. 2024, 22:2367-77. 10.1016\/j.cgh.2024.07.003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102328","article-title":"Comparative analysis of Resmetirom vs. FGF21 analogs vs. GLP-1 agonists in MASLD and MASH: network meta-analysis of clinical trials","volume":"12","author":"Ayesh H","year":"2024","unstructured":"Ayesh H, Beran A, Suhail S, Ayesh S, Niswender K. Comparative analysis of Resmetirom vs. FGF21 analogs vs. GLP-1 agonists in MASLD and MASH: network meta-analysis of clinical trials. Biomedicines. 2024, 12:10.3390\/biomedicines12102328","journal-title":"Biomedicines"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000670","article-title":"Early experience with resmetirom to treat metabolic dysfunction-associated steatohepatitis with fibrosis in a real-world setting","volume":"9","author":"Ravela N","year":"2025","unstructured":"Ravela N, Shackelford P, Blessing N, Yoder L, Chalasani N, Samala N. Early experience with resmetirom to treat metabolic dysfunction-associated steatohepatitis with fibrosis in a real-world setting. Hepatol Commun. 2025, 9:e0670. 10.1097\/HC9.0000000000000670","journal-title":"Hepatol Commun"},{"key":"ref21","unstructured":"EU regulator backs conditional authorisation for Madrigal's liver disease drug. (2025). Accessed. June 21, 2025: https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/eu-medicines-regulator-grants-conditional-authorisation-m...."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco AC","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al.. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018, 169:467-73. 10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000002150","article-title":"Clinical insights on Resmetirom: clinical indications, patient selection, and monitoring response to therapy","volume":"59","author":"Kaya E","year":"2025","unstructured":"Kaya E, Yilmaz Y, Alkhouri N. Clinical insights on Resmetirom: clinical indications, patient selection, and monitoring response to therapy. J Clin Gastroenterol. 2025, 59:412-9. 10.1097\/MCG.0000000000002150","journal-title":"J Clin Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69919","article-title":"Resmetirom: a systematic review of the revolutionizing approach to non-alcoholic steatohepatitis treatment focusing on efficacy, safety, cost-effectiveness, and impact on quality of life","volume":"16","author":"Bittla P","year":"2024","unstructured":"Bittla P, Paidimarri SP, Ayuthu S, Chauhan YD, Saad MZ, Mirza AA, Khan S. Resmetirom: a systematic review of the revolutionizing approach to non-alcoholic steatohepatitis treatment focusing on efficacy, safety, cost-effectiveness, and impact on quality of life. Cureus. 2024, 16:e69919. 10.7759\/cureus.69919","journal-title":"Cureus"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(25)01511-9","article-title":"WED-434 Use of noninvasive tests (NITs) to diagnose and follow nonalcoholic steatohepatitis (NASH) with liver fibrosis patients treated with Resmetirom","volume":"82","author":"Schattenberg JM","year":"2025","unstructured":"Schattenberg JM, Alkhouri N, Taub R,  Labriola D, Sanyal AJ, Ratziu V, Noureddin M. WED-434 Use of noninvasive tests (NITs) to diagnose and follow nonalcoholic steatohepatitis (NASH) with liver fibrosis patients treated with Resmetirom. Journal of Hepatology. 2025, 82:S556. 10.1016\/s0168-8278(25)01511-9","journal-title":"Journal of Hepatology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(25)01681-2","article-title":"SAT-418-YI Indication of resmetirom in patients with metabolic dysfunction associated steatohepatitis in the real-world setting - data from the german SLD-registry","volume":"82","author":"Messer E","year":"2025","unstructured":"Messer E, Petroff D, Schattenberg JM, et al.. SAT-418-YI Indication of resmetirom in patients with metabolic dysfunction associated steatohepatitis in the real-world setting - data from the german SLD-registry. Journal of Hepatology. 2025, 82:627-8. 10.1016\/s0168-8278(25)01681-2","journal-title":"Journal of Hepatology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(25)01507-7","article-title":"WED-429 The utility of noninvasive tests - LIVERFASt, FIB4 and vibrationcontrolled transient elastography (VCTE, Fibroscan) - in the initiation and monitoring of the therapy with TNR-beta agonist (resmetirom) in MASH patients","volume":"82","author":"Sandhu J","year":"2025","unstructured":"Sandhu J, Mehrara S, Munteanu M, Pagadala M, Mehta A, Lee J, Mantry P. WED-429 The utility of noninvasive tests - LIVERFASt, FIB4 and vibrationcontrolled transient elastography (VCTE, Fibroscan) - in the initiation and monitoring of the therapy with TNR-beta agonist (resmetirom) in MASH patients. Journal of Hepatology. 2025, 82:S554. 10.1016\/s0168-8278(25)01507-7","journal-title":"Journal of Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(25)01506-5","article-title":"WED-425 Validation of proposed non-invasive criteria for resmetirom treatment in metabolic-associatedliverdisease in clinical practice","volume":"82","author":"Olveira A","year":"2025","unstructured":"Olveira A, Crespo J, Samaniego LI, et al.. WED-425 Validation of proposed non-invasive criteria for resmetirom treatment in metabolic-associatedliverdisease in clinical practice. Journal of Hepatology. 2025, 82:S553-4. 10.1016\/s0168-8278(25)01506-5","journal-title":"Journal of Hepatology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(25)01446-1","article-title":"THU-470-YI Liver-related events are uncommon in patients meeting AASLD criteria for Resmetirom and are not seen in those with a liver stiffness measurement <10 kPa","volume":"82","author":"Yeow HX","year":"2025","unstructured":"Yeow HX, Forrest EH, Stanley A, Barclay ST. THU-470-YI Liver-related events are uncommon in patients meeting AASLD criteria for Resmetirom and are not seen in those with a liver stiffness measurement &lt;10 kPa. Journal of Hepatology. 2025, 82:S523-4. 10.1016\/s0168-8278(25)01446-1","journal-title":"Journal of Hepatology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(25)00412-x","article-title":"OS-097 Evaluating noninvasive diagnostic pathways for identifying MASH patients eligible for Resmetirom therapy: a real-world cohort analysis","volume":"82","author":"Dunn W","year":"2025","unstructured":"Dunn W, Singal AK, Asaad I, et al.. OS-097 Evaluating noninvasive diagnostic pathways for identifying MASH patients eligible for Resmetirom therapy: a real-world cohort analysis. Journal of Hepatology. 2025, 82:S66. 10.1016\/s0168-8278(25)00412-x","journal-title":"Journal of Hepatology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(25)01674-5","article-title":"SAT-407-YI Assessing early changes and responses to resmetirom therapy using real world single center data","volume":"82","author":"Saggese A","year":"2025","unstructured":"Saggese A, Buckholz A, Schwartz R, et al.. SAT-407-YI Assessing early changes and responses to resmetirom therapy using real world single center data. Journal of Hepatology. 2025, 82:S624. 10.1016\/s0168-8278(25)01674-5","journal-title":"Journal of Hepatology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(25)01698-8","article-title":"SAT-438 General characteristics of the patients prescribed Resmetirom: data derived from six tertiary care centers in the United States","volume":"82","author":"Alkhouri N","year":"2025","unstructured":"Alkhouri N, Singal AK, Asaad I, et al.. SAT-438 General characteristics of the patients prescribed Resmetirom: data derived from six tertiary care centers in the United States. Journal of Hepatology. 2025, 82:S634-5. 10.1016\/s0168-8278(25)01698-8","journal-title":"Journal of Hepatology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001037412.40234.5d","article-title":"S2011 Real-world characteristics of the patients with metabolic dysfunction-associated steatohepatitis prescribed resmetirom: data derived from two tertiary care centers in the United States","volume":"119","author":"Kaya E","year":"2024","unstructured":"Kaya E, Nadeem R, Kapoor H, et al.. S2011 Real-world characteristics of the patients with metabolic dysfunction-associated steatohepatitis prescribed resmetirom: data derived from two tertiary care centers in the United States. American Journal of Gastroenterology. 2024, 119:1438-9. 10.14309\/01.ajg.0001037412.40234.5d","journal-title":"American Journal of Gastroenterology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2025.100709","article-title":"A real-world experience with Resmetirom: tolerability and access","volume":"4","author":"Shuaibi S","year":"2025","unstructured":"Shuaibi S, Tobal I, Gore J, Ebiai R, Ozoral C, Therapondos G. A real-world experience with Resmetirom: tolerability and access. Gastro Hep Adv. 2025, 4:100709. 10.1016\/j.gastha.2025.100709","journal-title":"Gastro Hep Adv"},{"key":"ref36","unstructured":"Highlights of prescribing information - Rezdiffra (Resmetirom) tablets, for oral use. (2024). Accessed. July 6, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217785s000lbl.pdf."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001084","article-title":"Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis","volume":"81","author":"Younossi ZM","year":"2025","unstructured":"Younossi ZM, Stepanova M, Racila A, Henry L, Labriola D, Taub R, Nader F. Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology. 2025, 81:1318-27. 10.1097\/HEP.0000000000001084","journal-title":"Hepatology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.17122","article-title":"Value-based pricing of Resmetirom for metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Le P","year":"2025","unstructured":"Le P, Dasarathy S, Herman WH, et al.. Value-based pricing of Resmetirom for metabolic dysfunction-associated steatotic liver disease. JAMA Netw Open. 2025, 8:e2517122. 10.1001\/jamanetworkopen.2025.17122","journal-title":"JAMA Netw Open"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2393952","article-title":"Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)","volume":"27","author":"Fishman J","year":"2024","unstructured":"Fishman J, Kim Y, Paris\u00e9 H, Bercaw E, Smith Z. Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). J Med Econ. 2024, 27:1108-18. 10.1080\/13696998.2024.2393952","journal-title":"J Med Econ"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.17129","article-title":"The inherent value of treating metabolic dysfunction-associated steatohepatitis","volume":"8","author":"Lazarus JV","year":"2025","unstructured":"Lazarus JV. The inherent value of treating metabolic dysfunction-associated steatohepatitis. JAMA Netw Open. 2025, 8:e2517129. 10.1001\/jamanetworkopen.2025.17129","journal-title":"JAMA Netw Open"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(25)01474-6","article-title":"WED-384 Non-invasive identification of MASLD patients eligible for resmetirom treatment - data from a multicenter biopsy-proven MASLD cohort","volume":"82","author":"John K","year":"2025","unstructured":"John K, Franck M, Rau M, et al.. WED-384 Non-invasive identification of MASLD patients eligible for resmetirom treatment - data from a multicenter biopsy-proven MASLD cohort. Journal of Hepatology. 2025, 82:S538. 10.1016\/s0168-8278(25)01474-6","journal-title":"Journal of Hepatology"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2024.04.021","article-title":"Breakthrough in the treatment of metabolic associated steatotic liver disease: is it all over?","volume":"56","author":"Petroni ML","year":"2024","unstructured":"Petroni ML, Perazza F, Marchesini G. Breakthrough in the treatment of metabolic associated steatotic liver disease: is it all over?. Dig Liver Dis. 2024, 56:1442-51. 10.1016\/j.dld.2024.04.021","journal-title":"Dig Liver Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.9-a.s1","article-title":"Nonalcoholic steatohepatitis\/metabolic dysfunction-associated steatohepatitis emerging market: preparing managed care for early intervention, equitable access, and integrating the patient perspective","volume":"30","author":"Flavin B","year":"2024","unstructured":"Flavin B. Nonalcoholic steatohepatitis\/metabolic dysfunction-associated steatohepatitis emerging market: preparing managed care for early intervention, equitable access, and integrating the patient perspective. J Manag Care Spec Pharm. 2024, 30:S1-13. 10.18553\/jmcp.2024.30.9-a.s1","journal-title":"J Manag Care Spec Pharm"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2025.0178","article-title":"Metabolic and functional cross talk between the thyroid and liver","volume":"35","author":"Chng CL","year":"2025","unstructured":"Chng CL, Goh GB, Yen PM. Metabolic and functional cross talk between the thyroid and liver. Thyroid. 2025, 35:607-23. 10.1089\/thy.2025.0178","journal-title":"Thyroid"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1155\/ije\/6430023","article-title":"Resmetirom: the first disease-specific treatment for MASH","volume":"2025","author":"Mousa AM","year":"2025","unstructured":"Mousa AM, Mahmoud M, AlShuraiaan GM. Resmetirom: the first disease-specific treatment for MASH. Int J Endocrinol. 2025, 2025:6430023. 10.1155\/ije\/6430023","journal-title":"Int J Endocrinol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan WK","year":"2023","unstructured":"Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023, 32:197-213. 10.7570\/jomes23052","journal-title":"J Obes Metab Syndr"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le MH","year":"2022","unstructured":"Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, Nguyen MH. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022, 28:841-50. 10.3350\/cmh.2022.0239","journal-title":"Clin Mol Hepatol"},{"key":"ref48","unstructured":"New Drug Application (NDA). 217785, Accelerated Approval for Resmetirom Tablets. (2024). Accessed: 14-03-2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2024\/217785Orig1s000ltr.pdf."},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2402905","article-title":"A phase 3 trial of Resmetirom in NASH with liver fibrosis. Reply","volume":"390","author":"Harrison SA","year":"2024","unstructured":"Harrison SA, Taub R. A phase 3 trial of Resmetirom in NASH with liver fibrosis. Reply. N Engl J Med. 2024, 390:1632-3. 10.1056\/NEJMc2402905","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis M","year":"2024","unstructured":"Kokkorakis M, Boutari C, Hill MA, Kotsis V, Loomba R, Sanyal AJ, Mantzoros CS. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges. Metabolism. 2024, 154:155835. 10.1016\/j.metabol.2024.155835","journal-title":"Metabolism"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(25)00311-3","article-title":"LBO-002 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis","volume":"82","author":"Alkhouri N","year":"2025","unstructured":"Alkhouri N, Taub R, Lu X, et al.. LBO-002 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis. Journal of Hepatology. 2025, 82:S9-10. 10.1016\/s0168-8278(25)00311-3","journal-title":"Journal of Hepatology"},{"key":"ref52","article-title":"Multimodal AI predicts clinical outcomes of drug combinations from preclinical data","author":"Huang Y","year":"2025","unstructured":"Huang Y, Su X, Ullanat V, et al.. Multimodal AI predicts clinical outcomes of drug combinations from preclinical data. ArXiv. 2025,","journal-title":"ArXiv"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1186\/s43162-025-00468-z","article-title":"Resmetirom in the management of metabolic associated steatohepatitis (MASH): a review of efficacy and safety data from clinical trials","volume":"37","author":"Ogieuhi IJ","year":"2025","unstructured":"Ogieuhi IJ, Olatunji G, Kokori E, et al.. Resmetirom in the management of metabolic associated steatohepatitis (MASH): a review of efficacy and safety data from clinical trials. The Egyptian Journal of Internal Medicine. 2025, 37:Article number 78. 10.1186\/s43162-025-00468-z","journal-title":"The Egyptian Journal of Internal Medicine"},{"key":"ref54","unstructured":"FDA Adverse Events Reporting System (FAERS) Public Dashboard, Resmetirom (G). (2025). Accessed. July 6, 2025: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/45beeb74-30ab-46be-8267-5756582633b4\/state\/a...."},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.08.021","article-title":"Research techniques made simple: assessing risk of bias in systematic reviews","volume":"136","author":"Drucker AM","year":"2016","unstructured":"Drucker AM, Fleming P, Chan AW. Research techniques made simple: assessing risk of bias in systematic reviews. J Invest Dermatol. 2016, 136:e109-14. 10.1016\/j.jid.2016.08.021","journal-title":"J Invest Dermatol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/publications8040045","article-title":"Assessment of factors causing bias in marketing-related publications","volume":"8","author":"Morkunas M","year":"2020","unstructured":"Morkunas M, Rudien\u0117 E, Giri\u016bnas L, Dau\u010di\u016bnien\u0117 L. Assessment of factors causing bias in marketing-related publications. Publications. 2020, 8:45. 10.3390\/publications8040045","journal-title":"Publications"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.17226\/13219","article-title":"Ethical and Scientific Issues in Studying the Safety of Approved Drugs","year":"2012","unstructured":"Ethical and Scientific Issues in Studying the Safety of Approved Drugs. National Academies of Sciences, Engineering, and Medicine. The National Academies Press, Washington, DC; 2012. 10.17226\/13219"},{"key":"ref58","unstructured":"Committee for Medicinal Products for Human Use (CHMP) Opinion on Resmetirom (Rezdiffra). (2025). Accessed. July 6, 2025: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rezdiffra."},{"key":"ref59","unstructured":"Shafafiya Drug List. (2025). Accessed. 14-07-2025: https:\/\/shafafiyaportal.doh.gov.ae\/dictionary\/DrugCoding\/Drugs.xlsx."},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi ZM","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, Paik JM. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024, 22:1999-2010.e8. 10.1016\/j.cgh.2024.03.006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02958-z","article-title":"Opportunities and challenges following approval of resmetirom for MASH liver disease","volume":"30","author":"Lazarus JV","year":"2024","unstructured":"Lazarus JV, Ivancovsky Wajcman D, Mark HE, et al.. Opportunities and challenges following approval of resmetirom for MASH liver disease. Nat Med. 2024, 30:3402-5. 10.1038\/s41591-024-02958-z","journal-title":"Nat Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison SA","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, et al.. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023, 29:2919-28. 10.1038\/s41591-023-02603-1","journal-title":"Nat Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi K","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, et al.. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022, 28:528-62. 10.1016\/j.eprac.2022.03.010","journal-title":"Endocr Pract"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001440","article-title":"Call to action-Pediatric MASLD requires immediate attention to curb health crisis","author":"Hartmann P","year":"2025","unstructured":"Hartmann P, Mouzaki M, Hassan S, et al.. Call to action-Pediatric MASLD requires immediate attention to curb health crisis. Hepatology. 2025, 10.1097\/HEP.0000000000001440","journal-title":"Hepatology"},{"key":"ref65","unstructured":"US doctors prescribe Rezdiffra, note concern about patient costs. (2024). Accessed. 06-07-2025: https:\/\/liverdiseasenews.com\/news\/us-doctors-prescribe-rezdiffra-note-concern-about-patient-costs\/."},{"key":"ref66","unstructured":"Madrigal Patient Support. about our program. (2025). Accessed: July 6, 2025: https:\/\/madrigalpatientsupport.com\/about-madrigal-patient-support\/."},{"key":"ref67","unstructured":"Policy Communications. (2025). Accessed. July 6, 2025: https:\/\/www.aasld.org\/policy-communications#:~:text=Virtual%20Hill%20Day%20Report:%20March,research%2C%20treatment%2C...."},{"key":"ref68","article-title":"Overview of Health Technology Assessment Processes for Time-Limited Recommendations: CADTH Health Technology Review","author":"Mendell A","year":"2023","unstructured":"Mendell A, Vannabouathong C, Le K, et al.. Overview of Health Technology Assessment Processes for Time-Limited Recommendations: CADTH Health Technology Review. CADTH Health Technology Review. Canadian Agency for Drugs and Technologies in Health, 2023."},{"key":"ref69","unstructured":"A phase 3 study to evaluate safety and biomarkers of Resmetirom (MGL-3196) in patients with non-alcoholic fatty liver disease (NAFLD), MAESTRO-NAFLD-open-label-extension (MAESTRO-NAFLD-OLE). (2023). Accessed. July 14, 2025: https:\/\/www.clinicaltrials.gov\/study\/NCT04951219?term=RESMETIROM&amp;rank=1."},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02989-5","article-title":"Estimation of the eligible population for Resmetirom among adults in the United States for treatment of non-cirrhotic NASH with moderate-to-advanced liver fibrosis","volume":"41","author":"Fishman J","year":"2024","unstructured":"Fishman J, Kim Y, Charlton MR, Smith ZJ, O'Connell T, Bercaw EM. Estimation of the eligible population for Resmetirom among adults in the United States for treatment of non-cirrhotic NASH with moderate-to-advanced liver fibrosis. Adv Ther. 2024, 41:4172-90. 10.1007\/s12325-024-02989-5","journal-title":"Adv Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/390697-translating-trial-to-treatment-a-scoping-review-of-resmetirom-first-year-in-real-world-use-for-moderate-to-advanced-fibrosis-in-metabolic-dysfunction-associated-steatohepatitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T07:52:55Z","timestamp":1755417175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/390697-translating-trial-to-treatment-a-scoping-review-of-resmetirom-first-year-in-real-world-use-for-moderate-to-advanced-fibrosis-in-metabolic-dysfunction-associated-steatohepatitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,17]]},"references-count":70,"URL":"https:\/\/doi.org\/10.7759\/cureus.90268","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,17]]}}}